Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J; EMPRISE Europe and Asia Study Group. Karasik A, et al. Among authors: yabe d. Diabetes Metab. 2023 Mar;49(2):101418. doi: 10.1016/j.diabet.2022.101418. Epub 2023 Jan 3. Diabetes Metab. 2023. PMID: 36608816 Free article.
Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels.
Iwasaki M, Hoshian F, Tsuji T, Hirose N, Matsumoto T, Kitatani N, Sugawara K, Usui R, Kuwata H, Sugizaki K, Kitamoto Y, Fujiwara S, Watanabe K, Hyo T, Kurose T, Seino Y, Yabe D. Iwasaki M, et al. Among authors: yabe d. J Diabetes Investig. 2012 Oct 18;3(5):464-7. doi: 10.1111/j.2040-1124.2012.00214.x. J Diabetes Investig. 2012. PMID: 24843607 Free PMC article.
Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial.
Yabe D, Eto T, Shiramoto M, Irie S, Murotani K, Seino Y, Kuwata H, Kurose T, Seino S, Ahrén B, Seino Y. Yabe D, et al. Diabetes Obes Metab. 2017 Mar;19(3):442-447. doi: 10.1111/dom.12817. Epub 2016 Nov 29. Diabetes Obes Metab. 2017. PMID: 27800649 Free PMC article. Clinical Trial.
Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
Yabe D, Iwasaki M, Kuwata H, Haraguchi T, Hamamoto Y, Kurose T, Sumita K, Yamazato H, Kanada S, Seino Y. Yabe D, et al. Diabetes Obes Metab. 2017 May;19(5):739-743. doi: 10.1111/dom.12848. Epub 2017 Feb 21. Diabetes Obes Metab. 2017. PMID: 27990776 Free PMC article. Clinical Trial.
Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes.
Kuwata H, Okamoto S, Seino Y, Murotani K, Tatsuoka H, Usui R, Hamamoto Y, Kurose T, Seino Y, Yabe D. Kuwata H, et al. Among authors: yabe d. J Diabetes Investig. 2018 Sep;9(5):1153-1158. doi: 10.1111/jdi.12779. Epub 2017 Dec 26. J Diabetes Investig. 2018. PMID: 29172255 Free PMC article.
204 results